Cibus, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $123.1M
- Price
- $1.61
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.55%
- Volume
- 75.6K
About
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Quick stats
Shares outstanding76.4M
Computed float56.9M
Float / shares74.5%
Cash runway (months)2.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001705843
Websitehttps://www.cibus.com
AI Summary
AI-generated1/17
minorbullishpartnership
Cibus and Crystal Crop Protection Team Up to Improve India’s Mustard Crop
Cibus and India's Crystal Crop Protection announced an agreement to develop gene-edited traits in Brassica juncea (mustard), with Crystal Crop holding an exclusive license to evaluate and commercialize the traits in India.
India grows mustard on roughly 8.5 million hectares yet imports more than half its edible oil; Crystal Crop brings a distribution network of more than 14,823 partners across 23 states to commercialize improved seed at scale.
The deal extends Cibus' royalty-licensing model internationally and benefits from India's 2022 determination that gene-edited crops with no foreign DNA fall outside GMO rules, though no financial terms or commercial timelines were disclosed.
Red flags
- no financial terms, milestones, or commercialization timeline disclosed
- pre-revenue pathway -- revenues contingent on successful trait development and partner commercialization
- Cibus forward-looking statements flag need for additional near-term funding